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Progress in the treatment of Rheumatoid Arthritis (RA) in the last two decades has been remarkable, 
leading to substantial improvements in the quality of life for many patients.  This has arisen from 
two fundamental developments. Firstly, the advent of pathogenesis-led therapeutics has generated 
a growing armamentarium of effective medicines available to the practitioner  (1). The introduction 
of TNF inhibition arose from a careful in vitro cellular immunology and in vivo murine arthritis model 
programme that generated sufficient pre-clinical validation to encourage successful testing in RA of 
TNF inhibitors that had previously failed in sepsis studies.  Subsequently, other therapies emerged 
that antagonise pro-inflammatory cytokines (for example, IL-6), inhibit T-cell costimulatory 
activation or deplete CD20 positive B-cells (1). More recently, a small molecule inhibitor of 
intracellular signalling in the form of the JAK1 / JAK3 inhibitor tofacitinib has heralded a new era of 
targeted synthetic DMARDs. A second substantial development has arisen from the advent of 
“strategically smart” approaches encapsulated in ‘treat early’ and ‘treat to target’ approaches  (1). 
Together these developments have significantly improved the prognosis of patients with RA, 
reducing joint damage, functional disability, co-morbidity and mortality. Moreover, they have 
brought about the possibility of remission induction and maintenance of response in the treatment 
of RA, concepts which even two decades ago were inconceivable.   
Midst such excitement it is salutary to consider briefly the cost of this journey of improvement and 
learn lessons to inform further progress.  In particular, there have been numerous clinical targets 
selected on the basis of robust data sets which have failed to meet phase II or phase III trial success.  
This attrition rate may not be sustainable for either the pharmaceutical industry or the clinical trial 
community. This is pertinent since, in our view, there remains significant unmet clinical need in RA. 
True remission is still achieved only in a minority of patients and usually requires ongoing treatment 
with its attendant risks and significant financial cost. Moreover, there is a group of patients who 
become refractory to all existing therapies or who never respond in the first place.  Against this 
background of unmet clinical need, rising drug development costs, yet burgeoning knowledge about 
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disease pathobiology, it is timely to reconsider the methodology that might lead to the accurate 
identification of novel immune targets for use in the treatment of RA.    
The current edition of the journal contains a very interesting phase III clinical trial evaluating the use 
of the IL-17A inhibitor secukinumab in patients with active RA who have previously had an 
inadequate response to TNF inhibitors  (2).  The authors and editors alike are to be congratulated for 
bringing these data into the public domain – publishing such data comprises a significant step 
forwards in planning for success in the future. The trial examined the therapeutic impact of two 
doses of secukinumab compared with either abatacept or placebo.  While the primary outcome was 
met at the “statistical level” for ACR20 improvement at week 24 for the higher 150 mg dose of 
secukinumab, this was achieved by only a modest proportion of patients, while significant 
improvement in key secondary endpoints was not achieved. Overall, the study demonstrates, at 
best, only modest superiority for secukinumab over placebo, with a response that was probably 
inferior to that seen with abatacept and does not support further development of secukinumab for 
use in patients with RA who have previously failed TNF-inhibitors.  This study should be considered 
in the wider context of negative studies in RA for the IL-17 receptor inhibitor, which blocks IL-17RA  
(3), and modest benefits, at best, for ixekizumab, another IL-17A inhibitor  (4).  From this therapeutic 
trial set, we may conclude that IL-17A inhibition as monotherapy does not represent a satisfactory 
target for the treatment of RA.   
It is worth considering the experimental narrative that brought us to the present phase III clinical 
trial.  Interleukin 17A is a member of a large cytokine family that contains both pro- and anti-
inflammatory members.  It exhibits highly plausible biological effector functions, working either 
alone or especially in synergy with other inflammatory cytokines, such as TNF and IL-1, to promote 
synovial fibroblast activation, neutrophil activation and recruitment, B cell activation and antibody 
production and a variety of pro-destructive effects via osteoclast maturation and effector function  
(5).  In vivo experiments in relevant inflammatory arthritis models suggested that IL-17A occupies a 
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position of hierarchical primacy, rendering it an attractive therapeutic target.  The concept that Th17 
cells have dominant roles in a range of autoimmune murine models is now well-established and, 
together with the demonstration of IL-17A expression in human tissues of clinical relevance, has led 
to the adoption of IL-17A as a therapeutic target in a range of cutaneous, gastrointestinal, neurologic 
and articular immune mediated diseases  (5).   
These observations have translated into rather mixed clinical results when appropriate human 
clinical trials have been performed  (6).  Thus IL-17A blockade in psoriasis yields remarkable clinical 
responses, with PASI100 rates close to 50% representing complete clearance of disease. Successful 
trials have been conducted in psoriatic arthritis  (7–9) and axial spondyloarthropathy  (10), but with 
less spectacular musculoskeletal responses when compared to those achieved in skin  (11).  In 
contrast, no benefit accrued in patients with Crohn’s disease upon receipt of secukinumab  (12).  
From these studies we draw a number of conclusions. Firstly, the emerging group of IL-17A inhibitors 
represent a new class of medicines with viable pharmacologic and pharmacodynamic properties. 
Second, secukinumab and indeed other IL-17 inhibitors can be highly effective when used to treat 
disease states in which IL-17A enjoys functional hierarchical supremacy, such as cutaneous psoriasis. 
Thirdly, we have learned again from these studies that simply identifying an inflammatory cytokine 
as a potential target through documenting its presence in clinical tissues of relevance, postulating 
plausible biologic effector functions, is not sufficient to guarantee future therapeutic success.   
Moreover, we have learned once again that animal models of arthritis, whilst helpful in allowing us 
to dissect intact immune systems, have distinct translational limitations. Finally, the data suggest the 
value in building a compendium of trial outcomes across different inflammatory immune targets and 
immune mediated diseases to drive us towards a molecular taxonomy for inflammation medicine 
which could eventually complement the clinical phenotyping upon which current clinical trialling is 
based. 
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Where does this leave us in terms of current clinical target selections in RA? Happily, the field 
continues to progress with targets selected across a range of immune pathways. These include 
agents designed to inhibit innate immune activation, for example, those targeting Toll-like receptors 
and the intracellular molecular machinery that allows innate immune activation, for example, the 
inflammasome.  There are ongoing efforts to develop new effector cytokine inhibitors, including 
“look alike” agents targeting both IL-6 receptor and IL-6 ligand and novel agents targeting GMCSF or 
its receptor a subunit.  Other JAK inhibitors are emerging including baricitinib, a JAK 1/2 inhibitor  
(13,14), and filgotinib, a JAK1 inhibitor  (15,16). There is also interest in developing novel small 
molecule inhibitors of cellular signalling pathways, for example, inhibitors of the PI3 kinase family, 
BTK and also some interesting studies looking at epigenetic modifiers.  The search for immunological 
homeostasis continues - it is worth noting the development of cellular therapies, for example, the 
transfer of tolerogenic dendritic cells and also immune therapeutics designed to achieve the same 
effect in vivo, for example, using drug loaded liposomes.  Rather innovative approaches, such as 
those targeting the PAD enzyme system, stimulating the vagal nerve stimulation and modulating the 
neuroendocrine inflammatory system using gonadotropin releasing hormone antagonists (e.g. 
cetrorelix) have offered provisional evidence of benefit.  This plethora of potential targets may well 
yield new opportunities, however what marks all of them is the absence of a definitive, consistently 
applied discovery pathways that can give high levels of confidence a priori that they will either target 
a hierarchically sufficiently prominent molecule or a particularly vulnerable point in the 
inflammatory cascade  (17). 
How then could we change our approach to the development of new therapeutic agents whilst 
celebrating the successes annotated above?  It is important to recall the failure of clinical trials in RA 
that targeted, for example, CD4, CD5, IL-1, IL-12, IL-20 and IL-23.  These clinical trial development 
programmes all arose from rational and plausible pre-clinical biological packages and, although there 
were subtle differences between the weight of evidences and the nature of the experimental 
systems employed, few could be considered to be rash development decisions based on the 
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knowledge of that time.   Perhaps it is now appropriate to consider a systems-based approach to the 
development and validation of targets. We currently possess unparalleled access to digital 
information and computational power.  When brought together with the depth of biologic 
experimentation possible at the molecular and cellular level to generate high volume and quality of 
data, this offers intriguing and powerful possibilities.  Specifically, it may be possible to interrogate 
potential future therapeutic targets using in silico models of the rheumatic disease state, reflecting 
the accumulation of knowledge from pre-clinical biology studies, many clinical trials and ex vivo 
biomarker programmes, whether successful or not.   
Comprehensive datasets can be generated that describe the genome, epigenome, transcriptome, 
proteome and metabolome from a range of biological samples – the so called “polyome”. 
Bioinformatics algorithms capable of integrating the discrete information contained across the 
polyome are emerging.  Such data can be contributed from in vivo animal model studies in which 
pathways have been specifically targeted, together with in vitro leukocyte and synovial biology 
studies in which complex cellular contributions can be explored along with the signal pathways that 
subserve such biology. This should permit the creation of computational models that mimic RA 
pathways of inflammation and damage accrual that in turn, can be targeted in silico to estimate the 
likely outcomes of novel interventions.  In parallel, mode of action studies in RA patients in which 
blood and synovial responses to interventions should be mandatory so as to gather new ex vivo 
datasets that can be fed into the models to offer refinement on an ongoing basis. 
This systems approach to target discovery and validation could be usefully coupled with an 
increasing move towards stratification of the clinical and molecular phenotype of RA to improve 
success rates in the longer term.  We should give greater deference to the stage of disease for which 
a drug is to be developed – it is probably reasonable to assume that the immune system will adapt 
over time as articular damage accrues in RA and our approaches should be amended accordingly.  
Models will be required therefore for early disease but may equally be required as we consider 
Page 7 of 11 Arthritis & Rheumatology
 8 
development of agents for refractory RA.  For the latter we especially need to understand the 
mechanisms that underpin therapeutic failure and acquired loss of response. As we come to 
recognise the molecular heterogeneity of RA, so we will recognise the value of enriching the 
likelihood of responses to a given target by appropriate clinical selection of patients for trial entry.  
Similarly, adaptive trial designs may allow us to more quickly discard ineffective therapies and direct 
patients within the trial to those agents to which they are more likely to respond. In this respect, it is 
likely that important lessons can be learned, and adapted, from the rapidly expanding use of 
immunotherapies and innovative trial designs emerging in the treatment of cancer. Taken together, 
if we are more prepared to learn from unsuccessful trials and to preform detailed mechanistic 
analysis, not only of why studies have succeeded, but also of why others have failed, we will enrich 
the possibilities for future generations as they meet the challenges of the “RA disease” that we will 
bequeath to them.  
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